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Summary. In clinical trials, a biomarker (S ) that is measured after randomization and is strongly associated with the true
endpoint (T) can often provide information about T and hence the eﬀect of a treatment (Z ) on T. A useful biomarker can be
measured earlier than T and cost less than T. In this article, we consider the use of S as an auxiliary variable and examine the
information recovery from using S for estimating the treatment eﬀect on T, when S is completely observed and T is partially
observed. In an ideal but often unrealistic setting, when S satisﬁes Prentice’s deﬁnition for perfect surrogacy, there is the
potential for substantial gain in precision by using data from S to estimate the treatment eﬀect on T. When S is not close to
a perfect surrogate, it can provide substantial information only under particular circumstances. We propose to use a targeted
shrinkage regression approach that data-adaptively takes advantage of the potential eﬃciency gain yet avoids the need to
make a strong surrogacy assumption. Simulations show that this approach strikes a balance between bias and eﬃciency gain.
Compared with competing methods, it has better mean squared error properties and can achieve substantial eﬃciency gain,
particularly in a common practical setting when S captures much but not all of the treatment eﬀect and the sample size is
relatively small. We apply the proposed method to a glaucoma data example.
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1. Introduction
An intermediate biomarker (S ) in a clinical trial that is mea-
sured after randomization and is strongly associated with the
true endpoint (T) can often provide information about T and
hence the eﬀect of the treatment (Z ) on T. It is often an in-
termediate physical or laboratory indicator in a disease pro-
gression process and can be measured earlier and is easier
to collect than T. Examples of these types of biomarkers in-
clude CD4 counts in AIDS, blood pressure in cardiovascular
disease, and prostate-speciﬁc antigen in prostate cancer stud-
ies. In general, S will be a diﬀerent entity than T, but early
measurements are also used as biomarkers for the later mea-
surements, such as the interim height for adult height in girls
with Turner Syndrome by Venkatraman and Begg (1999). Dif-
ferent investigators use diﬀerent terminology for the role of
biomarkers. In this article, we call S a surrogate endpoint
when the potential use of S is to completely replace T to eval-
uate whether the treatment is eﬀective (Buyse and Molen-
berghs, 1998). Alternatively, when S is used to help provide
information or enhance the eﬃciency of the estimator of the
treatment eﬀect on T, we call S an auxiliary variable (Flem-
ing et al., 1994). In this article, we focus on the latter role.
Intuitively, since S and T are often closely associated, incorpo-
rating the information from S in estimating the actual eﬀect
of Z on T (denoted by Q) should lead to more eﬃcient esti-
mates, narrower conﬁdence intervals (CIs), and more powerful
tests.
A number of authors have explored the role of intermediate
biomarkers as auxiliary variables (Murray and Tsiatis, 1996;
Faucett, Schenker, and Taylor, 2002). However, the opinions
on their value have been mixed, as noted by Cook and Lawless
(2001). Correlation has often been the focus of investigations
into the extent of eﬃciency gain from using S to help estimate
the treatment eﬀect in a new trial (Buyse et al., 2000; Li and
Taylor, 2010). In general, the information recovered from S
appears to be very small unless S and T are very highly corre-
lated (Venkatraman and Begg, 1999). In this article, we focus
on the relationship between the extent of eﬃciency gain and
the structural relationship among S, T, and Z, deﬁned by the
coeﬃcients of a regression of T on S and Z. Even with ﬁxed
correlation between S and T given Z, if there is a strong struc-
tural relationship among S, T, and Z, a signiﬁcant eﬃciency
gain from using S is possible.
Here, we focus on a single trial setting where T is partially
observed, and S and Z are measured on everyone. Both S and
T are continuous and Z is binary. We assume a parametric
model for the joint distribution of S and T given Z, and be-
cause of the time sequence in which S and T are typically
measured, we factor this model as f (T |S, Z ) and f (S |Z ). We
assume linear models, with the full model for T |S, Z given
by T = β0 + β1S + β2Z + β3SZ + , where  is a normally
distributed error term. Our goal is to examine the extent of
eﬃciency gain through the use of S as an auxiliary variable
rather than as a surrogate variable, but we borrow the termi-
nology of surrogacy to describe the diﬀerent structural rela-
tionships between S and T. In a landmark paper concerning
surrogacy, Prentice (1989) called S a perfect surrogate end-
point (PES) when S fully captures the eﬀect of Z on T. For
our linear model, this condition becomes β1 = 0 and β2 =
β3 = 0. When β1 = 0 and either β2 = 0 or β3 = 0, S explains
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some, but not all, of the association between T and Z, and S
is called a partial surrogate (Wang and Taylor, 2002). More
speciﬁcally, when β1 = 0, β2 = 0, and β3 = 0, we call S an
additive partial surrogate (APAS); when β1 = 0, β2 = 0, and
β3 = 0, we call S an interactive partial surrogate (IPAS). We
are interested in estimating the eﬀect of Z on T under these
three structural relationships that describe the distribution of
T given S and Z.
Our numerical studies suggest that the gain in eﬃciency
from using S as an auxiliary variable depends strongly on
whether or not the structural relationship satisﬁes the PES,
APAS, or IPAS assumption. As we will show, if the PES struc-
ture is correctly assumed, there is the potential for substantial
gains in eﬃciency. On the other hand, when PES is incor-
rectly assumed, substantial bias can occur in the estimated
treatment eﬀect. Since in practice the validity of PES is un-
certain, there is the potential for an adaptive method that
realizes this eﬃciency gain if PES is true or approximately
true, but also limits the bias if PES is clearly not true. One
such strategy is to apply model selection methods, using p-
values to judge whether β2 and/or β3 equal to 0 and then
ﬁtting the selected model. However, this common practice ig-
nores the model uncertainty and can lead to high type I errors
(Albert et al., 2001) and substantial prediction error. From a
biological point of view, there are often multiple pathways
through which the treatment can aﬀect T, and a marker sel-
dom captures all the eﬀects on T. On the other hand, partial
surrogates that capture much but not all of the treatment
eﬀect are very plausible. For example, a biomarker can be
a good partial surrogate if it is in one of the few important
mechanistic pathways between Z and T or it can explain a
large amount of the treatment eﬀect on T. In these settings,
we propose an adaptive approach using a targeted ridge re-
gression method that shrinks β2 and β3 toward zero by an
amount that is supported by the data. This method is a com-
promise between the perfect surrogacy and partial surrogacy
models and provides better mean squared error properties by
striking a data-driven balance between bias and variance.
The article is organized as follows. In Sections 2 and
3, we conduct analytic and numerical studies to explore
the eﬃciency gain from S under the various structural as-
sumptions. In Section 4, we introduce the generalized ridge
regression method. In Section 5, we describe simulations
comparing this shrinkage approach with competing methods
including model selection and inverse probability weighting
(IPW). In Section 6, we apply the proposed method to a glau-
coma data set. In Section 7, we summarize and discuss our
ﬁndings.
2. Treatment Eﬀect Estimation and Surrogacy
Assumptions
Suppose that the number of study participants is n = n0 + n1
with n0, n1 in the Z = 0, 1 groups, respectively. The biomarker,
S, is measured on all n patients; T is available for a subset of
rj patients in the Z = j group (j = 0, 1) and r = r0 + r1. The
fraction of the subjects for whom T is not observed is p =
1 − r/n.
When S is an IPAS, we assume that the joint distribution
f (Ti , Si |Zi ) for participant i is given by two models:
Ti = β0 + β1Si + β2Zi + β3SiZi + ti
Si = α0 + α1Zi + si , (1)
where ti ∼ N (0, σ2t | s ) and si ∼ N (0, σ2ss ). For this model, the
marginal average treatment eﬀect is
QIPAS = E(T |Z = 1)− E(T |Z = 0)
= EE(T |S, Z = 1)− EE(T |S, Z = 0)
= β1α1 + β2 + β3α0 + β3α1.
We assume the missing data on T are missing at random
(MAR; Little and Rubin, 2002) for which the probability
of missingness depends only on observed data measures. In
our setting, this implies that we consider the missingness de-
pends on S and Z only. Under MAR, the likelihood of θ =
(β0, β1, β2, β3, α0, α1, σ2t | s , σ
2
ss ) based on the observed data is
given by: L(θ |S, T, Z) =∏r
i=1 f (Ti |Si , Zi , θ)
∏n
i=1 f (Si |Zi ,
θ). The estimate of QIPAS , QˆIPAS , can be obtained by substitut-
ing maximum likelihood estimates (MLEs) for the unknown
parameters. The large sample covariance matrix of θˆ can be
calculated as the inverse of the observed information ma-
trix I∗IPAS (θ). Let DIPAS (Q) = (
∂Q
∂ β 0
, ∂ Q
∂ β 1
, ∂ Q
∂ β 2
, ∂ Q
∂ β 3
, ∂ Q
∂ α 0
, ∂ Q
∂ α 1
) =
(0, α1, 1, α0 + α1, β3, β1 + β3). The asymptotic variance of
QˆIPAS can be calculated using the delta method as
V (QˆIPAS ) = DIPAS (Q)T I∗IPAS (θ)
−1DIPAS (Q).
Its estimate Vˆ (QˆIPAS ) can be obtained by replacing θ with the
MLE θˆ. Under the missing completely at random (MCAR)
assumption, for which the probability of missingness does not
depend on observed or unobserved data measures, Little and
Rubin (2002) noted that V (QˆIPAS ) can be approximated by
σ2t t0
r0
(
1 − ρ20
n0 − r0
n0
)
+
σ2t t1
r1
(
1 − ρ21
n1 − r1
n1
)
, (2)
where ρ0 and ρ1 denote the correlation between S and T in
the Z = 0, 1 group, respectively; σ2t t0 and σ
2
t t1 refer to V(T |
Z = 0) and V(T |Z = 1), respectively. Calculations in the Web
Appendix show that ρ20 =
β 21σ
2
s s
σ 2
t | s +β
2
1σ
2
s s
, ρ21 =
(β 1+β 3)2σ 2s s
σ 2
t | s +(β 1+β 3)
2σ 2s s
,
σ2t t0 = σ
2
t | s /(1 − ρ20), and σ2t t1 = σ2t | s /(1 − ρ21). The approxi-
mation (2) shows that the correlations, the fractions of miss-
ingness, σ2t t0, and σ
2
t t1 are important factors that impact the
variance of QˆIPAS .
If T is fully observed, without any distributional assump-
tion, the estimated treatment eﬀect would be QˆALL =
∑n 1
i=1
Ti/n1 −
∑n 0
i=1 Ti/n0 with variance V (QˆALL) = σ
2
t t0/n0 + σ
2
t t1/
n1. When T is partially observed, the treatment eﬀect esti-
mated solely based on the observed T is QˆCC =
∑r 1
i=1 Ti/r1 −∑r 0
i=1 Ti/r0 and its variance is V (Qˆcc ) = σ
2
t t0/r0 + σ
2
t t1/r1.
When S is an APAS, the treatment eﬀect on T is QAPAS =
β2 + β1α1. Under the MAR assumption, the asymptotic vari-
ance of QˆAPAS can be calculated in the same way as that
of QˆIPAS , but noting that I∗APAS is a 5 × 5 information ma-
trix. Under the MCAR assumption, the large sample variance
V (QˆAPAS ) can also be approximated by
σ2t t
r0
(
1 − ρ2 n0 − r0
n0
)
+
σ2t t
r1
(
1 − ρ2 n1 − r1
n1
)
, (3)
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where ρ2 = ρ20 = ρ21 =
β 21σ
2
s s
σ 2
t | s +β
2
1σ
2
s s
and σ2t t = σ2t | s /(1 − ρ2).
When the percent of missingness and σtt are ﬁxed, ρ2 is the
single most important factor that determines the extent of
eﬃciency gain from S.
When S is a perfect surrogate, the marginal treatment ef-
fect on T is QPES = β1α1. Under the MAR assumption, the
calculation of the asymptotic variance V (QˆPES ) follows closely
those for V (QˆIPAS ) and V (QˆAPAS ) with I∗PES being a 4 × 4 in-
formation matrix. Under the MCAR assumption, as shown in
the Web Appendix, the asymptotic variance can be approxi-
mated by
α21σ
2
t t (1 − ρ2)
rσ2ss +
(
r1 − r
2
1
r
)
α21
+
β21σ
2
ss
n1 − n
2
1
n
. (4)
Under the PES assumption, the factors that impact the eﬃ-
ciency gain include not only the correlation and the factors
associated with the correlation, but also α1.
3. Information Recovery and Surrogacy Assumptions
We conduct numerical studies based on the asymptotic vari-
ances to examine the impact of diﬀerent factors and diﬀerent
surrogacy assumptions on the eﬃciency gain from S. We as-
sume that n0 = n1 = 500 and the missingness mechanism is
MCAR. The true model is PES, APAS, or IPAS. We choose
diﬀerent combinations of θ, p, σ2t | s , and σ
2
ss . The variances
of the estimated treatment eﬀect on T are calculated for the
ﬁve diﬀerent estimates as V (QˆALL), V (QˆCC ), V (QˆIPAS ) in (2),
V (QˆAPAS ) in (3), and V (QˆPES ) in (4). We compute the rela-
tive eﬃciency (RE) deﬁned by the ratios of the variance of
V (QˆALL) to other variance estimates.
Numerical studies show that generally there is some im-
provement in the precision of Qˆ by incorporating S (see Web
Appendix). We plot the RE against ρ2 and α1 in Figure 1
when the true model is PES. When the ﬁtted model assumes
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Figure 1. Asymptotic relative eﬃciency (RE) compared with
that obtained from original data (ALL). Left: β0 = 0.5, β1 =
1, α0 = 1, α1 = 2, σ2t | s = 1, p = 0.7, and ρ
2 varies. Right: β0 =
0.5, β1 = 1, α0 = 1, σ2t | s = 1, p = 0.7, σ
2
ss = 0.5, ρ
2 = 0.333,
and α1 varies (n = 1000). This ﬁgure appears in color in the
electronic version of this article.
IPAS or APAS, the higher the correlation between S and T,
the higher the extent of eﬃciency gain from S. When we ﬁt
PES, the amount of information recovery from S depends on
the correlation and α1. When everything else holds constant,
the smaller the value of α1, the higher the amount of infor-
mation recovery from S. When the correlation increases, the
extent of eﬃciency gain also increases, and reaches a max-
imum RE (larger than 1) compared with ALL when ρ2 is
approximately 0.8 in this setting of true parameter values.
The extent of eﬃciency gain also highly depends on which
model we ﬁt. When ρ2 and α1 hold constant, ﬁtting either an
IPAS or APAS model can result in a similarly modest amount
of information recovery except when the correlation is unusu-
ally high. For large sample sizes, even though IPAS has one
additional parameter compared to APAS, they have similar
eﬃciencies. When the sample size is smaller (e.g., n1 = n2 =
60 in Figure 2), APAS gives more eﬃcient estimates than
IPAS. By ﬁtting the PES model, however, we can uniformly
improve the eﬃciency gain to a much greater extent. On the
other hand, if we make an incorrect PES assumption, the es-
timates of the marginal treatment eﬀect can be substantially
biased (Figure 2 and Web Tables 3–8). Thus, the surrogacy
assumption plays a central role in both the bias and the extent
of eﬃciency gain. In the next section, we propose a shrinkage
approach, a generalized ridge regression method (denoted by
Ridge), that avoids the need to make the surrogacy assump-
tions, sacriﬁces some bias to gain eﬃciency in a data adaptive
way, and gives better mean squared error properties.
4. Generalized Ridge Regression
We ﬁrst consider the situation when β3 = 0. As explained in
the Introduction, a biomarker is rarely a perfect surrogate in
practice, but it is more common for S to be a strong partial
surrogate and capture a large portion of the treatment eﬀect
on T. In these settings, a reasonable assumption is that β2
is close to but not exactly 0. We impose a prior distribution
on β2 such that β2 ∼ N (0, σ2b2 ), where σ2b2 is used to capture
the uncertainty about the departure from the perfect sur-
rogacy assumption. By assuming this prior distribution, the
generalized ridge regression model induces a shrinkage eﬀect
on βˆ2, which will data-adaptively shrink βˆ2 toward 0 with the
amount of shrinkage determined by how much S is close to be-
ing a perfect surrogate. Note that the frequentist counterpart
of the ridge regression is an L2 penalized regression. Here, we
describe two estimates, the ﬁrst is a full Bayes version, where
we treat σ2b2 as a hyperparameter with its own prior distribu-
tion; the second is an empirical Bayes version, where σ2b2 is
estimated directly from the data.
4.1 Full Bayes Estimator
When S is APAS, the joint distribution f (Ti , Si |Zi ) is ex-
pressed by two models in (1) with β3 = 0. We assume
β2 ∼ N (0, σ2b2 ). We specify a proper but diﬀuse prior of N(0,
a = 1002) for (β0, β1, α0, α1) and Gamma(c, d) for (σ−2t | s , σ
−2
b2
,
σ−2ss ), where the mean and variance of Gamma(c, d) are cd
and cd2, and c = 0.001, d = 1000. We use Gibbs sampling
to draw from the conditional posterior distributions (see the
Web Appendix) and obtain the joint posterior distributions
of the parameters. We can then easily obtain the posterior
distribution of the treatment eﬀect estimate (β2 + β1α1) and
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use the posterior mean as the estimate for Q, QˆRidge−FB and
the variance of the posterior distribution as the variance esti-
mate, Vˆ (QˆRidge−FB ).
4.2 Empirical Bayes Estimator
The advantage of the full Bayes estimation is that it accounts
for all the uncertainty associated with estimating every pa-
rameter. However, it is computationally intensive, particularly
for large sample sizes, so we consider an alternative empirical
Bayes estimator that is faster to compute.
We ﬁrst consider the situation when β3 = 0. The model
T |S, Z is given by Ti = β0 + β1Si + β2Zi + ti , where ti ∼
N (0, σ2t | s ). We specify the prior for β2 as N (0, σ
2
b2
). Let βT =
(β0, β1, β2), Xt = (1, S, Z ), and K = diag(0, 0, k2) where k2 =
σ2t | s /σ
2
b2
. Suppose σ2b2 and σ
2
t | s are known and noninformative
prior distributions are assumed for β0 and β1. The posterior
distribution of β follows a normal distribution with mean and
variance:
E(βˆ |Xt , T ) =
(
XTt Xt + K
)−1
XTt T,
V(βˆ |Xt , T ) =
(
XTt Xt + K
)−1
σ2t | s .
(5)
In practice, σ2b2 and σ
2
t | s are unknown and are estimated
directly from the data. Given β2, βˆ2 ∼ N (β2, σ2β 2 ), we obtain
the joint distribution of (βˆ2, β2) by multiplying the densities
of βˆ2 |β2 and β2 together, yielding the marginal density of βˆ2
as N (0, σ2β 2 + σ
2
b2
). The quantity σ2β 2 can be estimated from
the maximum likelihood ﬁt to Ti = β0 + β1Si + β2Zi +
ti . Since E(βˆ2) = 0, E{(βˆ2)2} = σ2β 2 + σ2b2 , and an estimate of
σ2b2 is max{0, (βˆ2)2 − σˆ2β 2}, alternatively βˆ22 can be considered
as a computationally easier and more conservative estimate
of σ2b2 . The two estimates of σ
2
b2
give similar results in our
simulations, thus we present results using βˆ22 . We then ﬁt the
model T |S, Z to get an MLE of σ2t | s . Then, we obtain the
empirical Bayes estimate of β and its variance by replacing
σ2t | s and σ
2
b2
in (5) with their estimates.
Let αT = (α0, α1) and Xs = (1, Z ), then the estimate αˆ
follows a normal distribution with mean and variance:
E(αˆ |Xs , S) =
(
XTs Xs
)−1
XTs S,
V(αˆ |Xs , S) =
(
XTs Xs
)−1
σ2ss .
We obtain the variance of αˆ by replacing σ2ss in V(αˆ) with its
estimate.
Let DRidge−EB (Q) = ( ∂Q∂ β 0 ,
∂ Q
∂ β 1
, ∂ Q
∂ β 2
, ∂ Q
∂ α 0
, ∂ Q
∂ α 1
) = (0, α1, 1, 0,
β1). The treatment eﬀect estimate QˆRidge−EB follows a normal
distribution with mean and variance estimated by:
Eˆ(QˆRidge−EB ) = βˆ1αˆ1 + βˆ2,
Vˆ(QˆRidge−EB ) = D(QˆRidge−EB )T
[
Vˆ(βˆ) 0
0 Vˆ(αˆ)
]
D(QˆRidge−EB ),
where the parameter estimate of β is the empirical Bayes es-
timate.
For both full Bayes and empirical Bayes versions of the
generalized ridge regression, we can easily extend the method
to the situation when β3 = 0 by assuming an additional prior
distribution of N (0, σ2b3 ) for β3 and following analogous pro-
cedure to those described above.
5. Simulation Studies
5.1 The Setup
We conduct extensive simulations to examine the proposed
methods and compare them with competing methods. We
generate 400 data sets using the models in (1) with the fol-
lowing true parameter values: β0 = 0.5, β1 = 1, α0 = 1, α1 =
2, σ2ss = 0.5, and σ
2
t | s = 1. We ﬁrst set β3 = 0. We vary β2
to reﬂect diﬀerent degrees of departure from the perfect sur-
rogacy assumption. Each data set contains the observations
from either 60, 120, or 480 subjects per treatment group. We
observe all of S, but only 20% of T (p = 0.8). The missing
data mechanism is MCAR. For each method and each data
set, we obtain the point estimate of Q and the corresponding
estimated standard error (SE), and an indicator variable for
the coverage for whether or not the 95% CI contains the true
value. We measure each method’s performance by the average
empirical bias (Bias), the average SE, the empirical standard
deviation (ESD), the empirical mean squared error (MSE =
ESD2 + Bias2) and the coverage rate (CR). For the Ridge-
FB method, the SE is given by the standard deviation of the
posterior distribution.
Many additional simulations are also performed. We vary
the values of α1, β1, and σ2t | s , and we also conduct all the
simulations under β3 = 0. We examine the properties of these
methods when there is no missingness. Even though MCAR
is often the primary missing mechanism in clinical trials, we
repeat the simulations under the more general MAR assump-
tion for missingness by allowing the probability of missing-
ness to depend on S and Z, speciﬁcally, logit(p) = γ0 + γ1
Z + γ2S with γ0 = 0.5, γ1 = 0.2, and γ2 = 0.18. In addition,
to examine how the methods perform under diﬀerent degrees
of correlations, we repeat the simulations listed above with
β3 = 0 under various σ2ss ranging from 0.1, 0.5, 1, to 5 that
correspond to ρ2 = 0.1, 0.33, 0.5, 0.83, respectively.
5.2 Simulation Results
Figure 2 shows the MSE and Bias of QˆRidge−FB relative to those
of QˆPES , QˆAPAS , and QˆIPAS and illustrates the data-adaptive
property of Ridge. For completeness, we also include the MSE
and Bias of QˆCC . Since the simulations are conducted under
MCAR, QˆCC and QˆALL only diﬀer by a multiplicative fac-
tor of r/n. The estimated variances Vˆ (QˆIPAS ), Vˆ (QˆAPAS ), and
Vˆ (QˆPES ) are calculated based on the observed information
matrix. When β2 = 0, ﬁtting an APAS or IPAS model can
result in much larger MSEs and smaller eﬃciency gains rela-
tive to ﬁtting a PES model. All methods give unbiased esti-
mates. When β2 departs further from 0, ﬁtting a PES model
leads to increasingly larger Bias and MSE compared to ﬁtting
APAS and IPAS models. When β2 is 0 or close to 0, Ridge-
EB retains a lot of the eﬃciency gain achieved by ﬁtting a
PES model without introducing appreciable bias. When β2 is
much diﬀerent from 0, Ridge-EB gives estimates with MSEs
similar to those obtained by ﬁtting an APAS or IPAS model
without the substantial bias resulted from ﬁtting an incorrect
PES model. Hence, Ridge-EB appears to strike a good bal-
ance between eﬃciency gain and bias, depending on the true
nature of the relationship between S and T. This illustrates
the data-adaptive capacity of Ridge-EB. These properties are
more pronounced in small samples than in large samples; for
example, β2 can be relatively larger for Ridge-EB to retain a
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Figure 2. Comparison of Ridge-EB, IPAS, APAS, PES, and CC in terms of MSE and bias by sample size and β2 from 400
simulated data sets. β0 = 0.5, β1 = 1, β3 = 0, α0 = 1, α1 = 2, σ2ss = 0.5, σ
2
t | s = 1, ρ
2 = 0.333, and p = 0.8. This ﬁgure appears
in color in the electronic version of this article.
large amount of eﬃciency gain in smaller samples (n1 = n2 =
60) than that in larger samples (n1 = n2 = 480). Note that as
β2 deviates further from 0, the shape of MSE line for Ridge-
EB generally increases before decreasing, a property that is
largely driven by the bias.
We then compare Ridge-EB, Ridge-FB with alternative
methods, including a two-stage model selection method
(MdlSel) and an IPW method (Horvitz and Thompson, 1952).
These are all methods that might be used in practice. The
MdlSel method ﬁrst tests that model among APAS, IPAS,
and PES is not contradicted by the data. Speciﬁcally, we
used the backward elimination approach (selection criterion:
p-value <0.05) to select the model. The selected model is
then used as the correct model to obtain the estimate of
Q (QˆMdlSel ) and its variance Vˆ (QˆMdlSel ). The IPW method
is mostly used to reduce bias but can also be applied to
utilize the information from auxiliary variables when T is
partially observed. Let Δi be the indicator for whether Ti
is observed or not (1 for being observed and 0 otherwise).
Denote πi = Pr(Δi = 1). We obtain the estimated πi (πˆi )
by ﬁtting the saturated model: logit{Pr(Δi = 1)} = δ0 +
δ1Si + δ2Zi + δ3SiZi . The treatment eﬀect can be esti-
mated by: QˆIPW = {
∑n
i
Δi
πˆ i
Ti I(Zi = 1)/
∑n
i
Δi
πˆ i
I(Zi = 1)} −
{∑n
i
Δi
πˆ i
Ti I(Zi = 0)/
∑n
i
Δi
πˆ i
I(Zi = 0)}.
The comparisons of the MSE and CR properties of
QˆRidge−EB , QˆRidge−FB , QˆMdlSel , QˆIPW , and QˆCC are illustrated
in Figure 3. On average, CC gives the highest MSEs. Both
Ridge-FB and Ridge-EB are data adaptive. When the sam-
ple size is large, Ridge-FB and Ridge-EB have very simi-
lar performances. However, there are subtle diﬀerences, par-
ticularly in small samples where Ridge-EB gives below-
nominal-level CRs and Ridge-FB oﬀers uniformly higher and
closer-to-nominal CRs than any other method. Unlike its com-
petitors, Ridge-FB accounts for all the uncertainty associated
with estimating the variance parameters. Generally, there is
more shrinkage toward 0 using Ridge-FB than using Ridge-EB
and the MSEs from Ridge-FB are often smaller than Ridge-
EB when β2 is 0 or close to 0; however, Ridge-EB is more ro-
bust and less biased when there is a large departure in β2 from
0 and often leads to smaller MSEs than Ridge-FB in these sit-
uations. MdlSel is also data adaptive, but, unlike Ridge, its
performance depends on the available power to choose the
correct model. When the power is small (e.g., when β2 and
β3 are moderate in size, or when the sample size is small),
Ridge can achieve smaller MSEs than MdlSel. On the other
hand, when the power is suﬃcient (e.g., when the size is 120
or 480 per group and when β2 and β3 are either ≈ 0 or very
large), MdlSel and Ridge have similar performances. In gen-
eral, MdlSel underestimates the variance, more so in smaller
samples which results in lower-than-nominal-level CRs. The
IPW method does not have the data-adaptive property and
cannot take advantage of the various plausible surrogacy as-
sumptions. Regardless of the magnitude of β2, the amount
of eﬃciency gain from utilizing S to estimate QIPW stays the
same. When β2 is close to 0, Ridge has a clear advantage
over IPW and gives considerably smaller MSEs particularly
for small sample sizes. The biases of these estimates can be
found in Web Tables 5 and 6. The Ridge methods often re-
sult in estimates with larger biases than CC; they also give
larger biases than IPW except for in very small samples. For
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Figure 3. Comparison of Ridge-EB, Ridge-FB, MdlSel, IPW, and CC in terms of MSE and coverage rate by sample size and
β2 from 400 simulated data sets. β0 = 0.5, β1 = 1, β3 = 0, α0 = 1, α1 = 2, σ2ss = 0.5, σ
2
t | s = 1, ρ
2 = 0.333, and p = 0.8. This
ﬁgure appears in color in the electronic version of this article.
MdlSel, the extent of bias relative to Ridge also depends on
the available power to choose the correct model.
Additional simulation results can be found in the Web Ap-
pendix. With diﬀerent values of α1, β1, and σ2t | s , the ﬁndings
are similar as above. When β3 = 0, the results show similar
patterns for all methods considered. With diﬀerent correla-
tions, the ﬁndings across simulations are also very similar;
in addition, we ﬁnd that the greater the magnitude of the
eﬃciency gain can achieve from PES compared with APAS
and IPAS under β2 = β3 = 0, the greater the amount of ef-
ﬁciency gain Ridge can retain. When there is no missingness,
the ﬁndings regarding PES, APAS, IPAS, MdlSel, and Ridge
are similar to those given above but IPW is not applicable.
When the missingness depends on S and Z under MAR, the
estimates from CC and PES are prone to large biases; how-
ever, the properties of APAS, IPAS, IPW, MdlSel, and Ridge
are similar to those under MCAR. As a reviewer points out,
missingness may be explained by covariates other than S and
Z and if so, we need to incorporate these other covariates in
our models to obtain valid estimates.
6. Application to a Glaucoma Study
We apply these methods to data from the Collaborative Initial
Glaucoma Treatment Study (CIGTS) (Musch et al., 2009).
Glaucoma is a group of diseases that cause vision loss and is a
leading cause for blindness. Elevated pressure in the eyes (i.e.,
intraocular pressure, IOP), is a major risk factor of glaucoma.
The Advanced Glaucoma Intervention Study (AGIS) demon-
strated that when IOP reduction from baseline is substantial,
progression of visual ﬁeld loss can be prevented (Musch et al.,
2009). The CIGTS is a randomized trial to compare the ef-
fects of two initial treatment strategies, immediate ﬁltration
surgery (Z = 1) and medications (Z = 0), on reducing IOP for
newly diagnosed open-angle glaucoma patients. Patients were
enrolled between 1993 and 1997. The IOP level (in mmHg)
has been measured at diﬀerent time points following random-
ization. We deﬁne the IOP measurements at the 102nd month
as T and IOP at the 12th month as S. Due to dropout, there
are many fewer patients at the later periods than at the earlier
periods. A total of 160 patients have IOP measured at both
months 12 and 102, and 413 patients have IOP measured only
at month 12. We ﬁt a logistic regression for the probability
of missingness that is found not to be signiﬁcantly associated
with either S or Z. The correlation between S and T is 0.456.
Summary statistics are presented in Table 1.
Table 1
Summary statistics from CIGTS data. IOP at the 102nd
month is the true endpoint and IOP at the 12th month is the
biomarker.
Medicine Surgery
IOP observed at 12th and 102nd month
Number of patients 86 74
IOP at 12th month: mean (SE) 17.9 (3.29) 14.1(4.96)
IOP at 102nd month: mean (SE) 17.5 (4.67) 15.1 (4.61)
IOP missing at 102nd month
Number of patients 206 207
IOP at 12th month: mean (SE) 18.2 (3.80) 14.3 (5.19)
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Table 2
Quantity of interest: diﬀerence in the IOP reduction at the
102nd month between medicine and surgery treatments.
Estimates from eight methods are presented here. Note that
the CI from IPW is obtained using bootstrapping and the
p-value is calculated as the probability of an observation from
a standard normal distribution that is less or equal to the ratio
of the estimate over its standard error (or the posterior
standard deviation when Ridge-FB is considered). IOP at the
102nd month as true endpoint and IOP at the 12th month as
the biomarker.
Estimation
method Estimate 95 % CI CI width p-value
CC −2.391 (−3.844, −0.937) 2.907 0.00058
IPW −2.387 (−3.726, −1.048) 2.678 0.00024
IPAS −2.419 (−3.792, −1.046) 2.746 0.00028
APAS −2.400 (−3.765, −1.034) 2.731 0.00029
PES −1.833 (−2.490, −1.176) 1.315 2.30 × 10−9
MdlSel −1.833 (−2.490, −1.176) 1.315 2.30 × 10−9
Ridge-EB −2.094 (−3.138, −1.049) 2.089 0.000047
Ridge-FB −2.019 (−3.033, −1.006) 2.027 0.000043
The S |Z model is based on all 413 patients and the T |S,
Z models are based on 160. By assuming IPAS, we ob-
tain the MLEs and their 95% CIs: βˆ1 = 0.61 (0.012, 1.20),
βˆ2 = 0.87 (−4.99, 6.74), and βˆ3 = −0.094 (−0.44, 0.25). As-
suming APAS, we have: βˆ1 = 0.45 (0.29, 0.61), βˆ2 = −0.69
(−2.16, 0.78). Assuming PES, we have βˆ1 = 0.48 (0.33, 0.63).
While the model selection method supports the PES assump-
tion, there is considerable uncertainty about the validity of
that assumption because the number of complete cases is rel-
atively small and power is limited. However, the preliminary
analysis implies that S can capture most of the treatment ef-
fect on T. Table 2 shows the estimates of the treatment diﬀer-
ence, their 95% CIs and p-values. The Ridge method assumes
β3 = 0. For Ridge-FB, we choose c = 0.001 and d = 1000
in the prior distributions. Although the treatment diﬀerence
between two groups is statistically signiﬁcant simply based
on CC without using S, we can investigate the properties of
diﬀerent methods based on the CIs and p-values. Fitting ei-
ther the IPAS or APAS model or applying the IPW method
results in CIs with width slightly narrower than that from the
CC method, suggesting limited eﬃciency gain from utilizing
S. Fitting the PES model leads to substantial eﬃciency gain;
however, the estimate is quite diﬀerent from others, perhaps
suggesting bias from failure of the PES assumption. Results
from ﬁtting Ridge-FB and Ridge-EB are comparable, giving
estimates between those of IPAS and PES, with lower vari-
ances than IPAS. The results illustrate the data-adaptive and
bias-variance trade-oﬀ feature of the Ridge methods.
7. Discussion
In this article, we propose the use of generalized ridge re-
gression to incorporate the information from S to estimate
the treatment eﬀect on T when the underlying relationship
between the biomarker and the true endpoint is not fully
known. Without the need to make surrogacy assumptions,
ridge regression can directly take advantage of the struc-
tural relationship between S and T, and increase the infor-
mation recovery from S and, hence increase precision. When
S captures much of the treatment eﬀect, the generalized ridge
regression method can retain most of the considerable eﬃ-
ciency gain achieved under the perfect surrogacy assump-
tion. When S only captures a modest amount of the treat-
ment eﬀect, our method can achieve eﬃciency comparable to
that under partial surrogacy assumptions, while limiting the
bias resulting from an incorrect perfect surrogacy assumption.
Our method achieves better mean squared error properties
by data-adaptively making the bias and variance trade-oﬀ,
particularly in a common setting when S captures most but
not all of the treatment eﬀect and the sample size is rela-
tively small. Note that although generalized ridge regression
provides a biased estimator of the treatment eﬀect in ﬁnite
samples, the estimator is consistent and the bias goes to zero
when the sample sizes are inﬁnitely large.
The ridge regression methods outperform the model selec-
tion procedure in terms of MSE, bias, and CR in situations
where the power to detect the correct assumption is relatively
small and the uncertainty of a model selection procedure is
very large. Unlike the model selection method, the ridge re-
gression method does not remove any variable, so it cannot
achieve full eﬃciency when the true parameter β2 is exactly
equal to 0. However, this may not be a serious limitation as
previous empirical studies have shown that it is unlikely for
S to be a perfect surrogate (Fleming and DeMets, 1996).
Utilizing S in predicting a treatment eﬀect when T is par-
tially observed is essentially a missing data problem. Com-
pared with the generalized ridge regression, the IPW method
is robust; however, it requires us to model the probability of
missingness, and it neither has the variance-bias trade-oﬀ fea-
ture of the ridge regression nor directly takes advantage of the
nature of the relationship between S and T. Hence, when S
is close to being perfect surrogate, our ridge method can give
smaller MSEs and achieve more eﬃciency gain than IPW. A
comparison with the alternative IPW methods (Scharfstein,
Rotnitzky, and Robins, 1999) is also worthy of investigation.
Many extensions of the generalized ridge regression method
can be made in the biomarker context. When multiple
biomarkers are considered, there could be even stronger moti-
vation for the use of a ridge regression method, since a greater
percentage of the treatment eﬀect may be captured by the
biomarkers. The idea can also be extended to the cases when
S and T are diﬀerent data types, such as time-to-event data.
In summary, generalized ridge regression is an area worthy of
further study and implementation in the biomarker context.
8. Supplementary Materials
Web Appendices and Tables referenced in Sections 2, 3, 4.1,
and 5.2 are available under the Paper Information link at the
Biometrics website http://www.biometrics.tibs.org.
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